


## Curriculum Vitae

<b>Name</b>	<b>Jae Lyun Lee</b>	
<b>Current Position &amp; Affiliation</b>	<b>Professor, Asan Medical Center, University of Ulsan College of Medicine</b>	
<b>Country</b>	<b>South Korea</b>	

### Educational Background

1. Philosophy Doctor from Ulsan University Graduate School of Medicine (Mar 2005~Aug 2007)
2. Master of Medical Science from Yeungnam University Graduate School of Medicine in 2005
3. Bachelor of Medical science (Medical Doctor degree) from Yeungnam University School of Medicine in 1993

### Professional Experience

1. Mar 2003 – Aug 2004. Full-time instructor of Oncology-Hematology, Department of Medicine, Yeungnam University College of Medicine, Daegu, Korea
2. Sep 2004 ~ Feb 2011. Assistant professor, Division of Oncology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
3. Mar 2011 ~ Mar 2017. Associate professor, Division of Oncology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
4. April 2009 ~ June 2010, Honorary Clinical Fellow to the Genitourinary Disease-Oriented Working Group and Phase I Program, UW Carbone Cancer Center, Madison, WI, USA.
5. Mar 2017 ~ . Professor, Division of Oncology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
6. Jan 2019 ~, ESMO Faculty, GU Cancer
7. Feb 2019 ~, Chief of KCSG GU/GY Cancer Committee

8. Sep 2020 ~, Editorial Board member of Cancer Research and Treatment, Korea Cancer Association.

## Professional Organizations

1. Korean Cancer Association (KCA)
2. Korean Cancer Study Group (KCSG)
3. Korean Society of Medical Oncology (KSMO)
4. Korean Urologic Oncology Society (KUOS)
5. American Society of Clinical Oncology (ASCO)
6. American Association for Cancer Research (AACR)
7. European Society of Medical Oncology (ESMO)
8. European Association of Urology (EAU)

## Main Scientific Publications

1. Park I, Kim BS, Lim HY, Kim HJ, Lee HJ, Choi YJ, et al. Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomised phase II study (COACH, KCSG GU10-16). *Eur J Cancer*. 2020;127:183-90.
2. Hwang I, Park I, Yoon SK, Lee JL. Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors. *Clin Genitourin Cancer*. 2020;18(2):e122-e33.
3. Choueiri TK, Heng DYC, Lee JL, Cancel M, Verheijen RB, Mellemaard A, et al. Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial. *JAMA oncology*. 2020;6(8):1247-55
4. Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. *Lancet Oncol*. 2020;21(12):1574-88